Administration of T84.66-LCHA-4-1BBL at all three tested doses (1, 3 and 10 mg/kg) resulted in the enhancement of CEA-TCB-mediated tumor growth inhibition (Figure 5A), exhibiting a clear dose-dependent trend. The gene discussed is CEACAM5; the disease is neoplasm.